This page shows you your search results in order of date. This is page number 17.
Order by Relevance | Date
Total 2042466 results found since Jan 2013.
Dipeptidyl peptidase 4 inhibitor reduces tumor-associated macrophages and enhances anti-PD-L1-mediated tumor suppression in non-small cell lung cancer
ConclusionsAnagliptin can enhance PD-L1 blockade efficacy in NSCLC by inhibiting macrophage differentiation and M2 macrophage polarization, and combination therapy may be a promising strategy for treating PD-L1 blockade therapy-resistant patients with NSCLC.
Source: Clinical and Translational Oncology - September 21, 2023 Category: Cancer & Oncology Source Type: research
Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional (R21 Clinical Trial Not Allowed)
Funding Opportunity RFA-DA-25-017 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to: 1.Support mining of SCORCH data to identify cell types, transcripts, enhancers, or transcriptional networks that play a role in HIV/ART or SUD molecular responses 2.Support functional validation studies (e.g. epigenomic or transcriptomic manipulation, high throughput secondary screening, etc.) to confirm or deny a biological role for data-mined cell types, transcripts, enhancers, or transcriptional networks in HIV/ART or SUD molecular responses 3.Provide foundational knowledge for understanding SUD and/or H...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 21, 2023 Category: Research Source Type: funding
Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-DA-25-016 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to: 1.Support mining of SCORCH data to identify cell types, transcripts, enhancers, or transcriptional networks that play a role in HIV/ART or SUD molecular responses 2.Support functional validation studies (e.g. epigenomic or transcriptomic manipulation, high throughput secondary screening, etc.) to confirm or deny a biological role for data-mined cell types, transcripts, enhancers, or transcriptional networks in HIV/ART or SUD molecular responses 3.Provide foundational knowledge for understanding SUD and/or H...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 21, 2023 Category: Research Source Type: funding
Single Source: Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Coordination, Analysis, and Scientific Outreach (UM1 Clinical Trial Not Allowed)
Funding Opportunity RFA-DA-25-015 from the NIH Guide for Grants and Contracts. To establish a Data Center to coordinate and analyze single cell and other molecular data sets generated by Single Cell Opioid Responses in the Context of HIV (SCORCH) and other NIDA-funded HIV and substance use disorder projects and to make the data findable, accessible, interoperable, and reusable (FAIR) to enable secondary analyses by the scientific community.
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 21, 2023 Category: Research Source Type: funding
A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody
Conditions: Lung Cancer; TKI Resistance; EGFR Sensitive Mutation; Anlotinib; Pianzumab Interventions: Drug: Anlotinib; Drug: Penpulimab Sponsors: Degan Lu; Wu Jieping Medical Foundation Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer
Conditions: Advanced Solid Tumor; Refractory Tumor Interventions: Radiation: Radiotherapy; Drug: PD-1/PD-L1 inhibitor; Drug: Granulocyte-macrophage colony-stimulating factor subcutaneous injection; Drug: Interleukin 2 subcutaneous injection; Drug: Endostatin Sponsor: Second Affiliated Hospital of Soochow University Recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption
Conditions: NAFLD; MASLD; Mild Inflammatory Context Intervention: Dietary Supplement: TOTUM-448 Sponsors: Valbiotis; Clinic'n'Cell; University Hospital, Clermont-Ferrand Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma
Conditions: Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-cell Lymphoma Intervention: Biological: RC19D2 cell injection Sponsor: Beijing Yongtai Ruike Biotechnology Company Ltd Recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Condition: Large B-Cell Lymphoma Interventions: Drug: Glofitamab; Drug: Polatuzumab vedotin; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Prednisone Sponsor: Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Needs and Preferences of Patients With Head-neck Cutaneous SCC
Conditions: Cutaneous Squamous Cell Carcinoma; Cutaneous Squamous Cell Carcinoma of the Head and Neck; Squamous Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck; Squamous Cell Carcinoma of the Head and Neck; Skin Cancer; Patient Satisfaction; High-Risk Cance r; Preference, Patient; Decision Making; Interview Intervention: Other: Regular care with additional administration of a semi-structured interview Sponsor: Maastricht University Medical Center Active, not recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer Intervention: Drug: PLB1004 Sponsor: Avistone Biotechnology Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
Conditions: Head Neck; Squamous Cell Carcinoma of Head and Neck Interventions: Drug: Pembrolizumab; Drug: Magrolimab; Drug: cetuximab; Drug: Docetaxel Sponsors: M.D. Anderson Cancer Center; Gilead Sciences Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma
Condition: Renal Cell Carcinoma Intervention: Drug: HS-10516 Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
Condition: Esophageal Squamous Cell Carcinoma Interventions: Drug: Carrelizumab; Drug: Paclitaxel injection; Drug: Cisplatin; Radiation: Concurrent chemoradiotherapy Sponsor: The First Affiliated Hospital with Nanjing Medical University Enrolling by invitation
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer
Condition: Neoplasms Interventions: Drug: GSK3901961; Drug: Cyclophosphamide; Drug: Fludarabine Sponsor: GlaxoSmithKline Terminated
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
